Tekmira Amends Deal with Hana Biosciences for Non-RNAi Legacy Products | GenomeWeb

Tekmira Pharmaceuticals said this week that it has amended its licensing deal with Hana Biosciences for three non-RNAi chemotherapy drug candidates in a move that will eliminate future payments to former debt holders.

In 2006, Tekmira licensed the legacy products to Hana, which assumed all expenses associated with their development in exchange for milestones and royalties. Under the terms of the amended deal, Hana will make a $5.75 million payment to Tekmira, which has agreed to reduce certain future payments associated with the drugs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.